Century Therapeutics, Inc. - Common Stock — Bilancio Trimestrale (NASDAQ:IPSC) | MetaTrader

Apri il grafico completo Full chart

Notizie

Mizuho avvia la copertura di Century Therapeutics con rating Outperform

H.C. Wainwright alza il target su Century Therapeutics per il potenziale nella terapia del diabete

Century Therapeutics aggiorna il programma di offerta azionaria con 131,6 milioni di dollari rimanenti

Leerink reiterates Market Perform on Century Therapeutics stock

TD Cowen avvia la copertura su Century Therapeutics con rating Buy

TD Cowen initiates Century Therapeutics stock rating at Buy

Clear Street ribadisce il rating Buy su Century Therapeutics a $6,60

Oracle, Palantir among market cap stock movers on Monday

Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know

Century Therapeutics stock price target raised to $4 from $2 at Piper Sandler

Clear Street riduce il target di prezzo delle azioni di Century Therapeutics a $6,60

Century Therapeutics stock price target lowered to $6.60 at Clear Street